EGFR and lung adenocarcinoma: However, gefitinib is the first targeted agent to be approved for the treatment of EGFR mutation-positive lung adenocarcinoma, which has showed evident clinical efficacy, particularly among non-smokers, East Asian females and patients with adenocarcinoma (6,7).